Developing drugs for drug-resistant, life threatening infections.
We intend to develop and commercialize novel therapeutic agents to treat life-threatening infections, including those caused by drug-resistant pathogens. The increasing prevalence of antibiotic resistance among bacterial pathogens has been widely recognized as an urgent public health threat by the CDC, the WHO and the Infectious Disease Society of America.
Our most advanced program, CF-301 (“exebacase”) is an investigational novel lysin that targets Staph aureus, including methicillin-resistant (“MRSA”) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis. We recently announced positive topline results from this first-in-patient Phase 2 superiority study of exebacase, which showed clinically meaningful improvement in clinical responder rates among patients treated with exebacase in addition to standard-of-care (“SOC”) antibiotics compared to SOC antibiotics alone. We have developed a novel, engineered variant of exebacase, CF-296, with potential as a targeted therapy for deep-seated, invasive biofilm-associated Staph aureus infections such as prosthetic joint infections. Our lysin research efforts are focused on a broad-based Gram-negative discovery program which aims to identify, optimize and develop lysins that target deadly Gram-negative pathogens. We have discovered and engineered lysins with potent activity against drug-resistant Pseudomonas aeruginosa (“P. aeruginosa”) bacteria, a major cause of morbidity and mortality in patients with hospital acquired pneumonia and a major medical challenge for patients with cystic fibrosis. We have also discovered a novel class of phage-derived lytic agents, known as amurin peptides, which have displayed potent activity against a wide range of Gram-negative pathogens in preclinical studies, including deadly, drug-resistant P. aeruginosa, Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii and Enterobacter cloacae bacteria species.
*Exebacase has been granted Fast Track Designation from the FDA for the treatment of Staph aureus bacteremia.
Costs By 2050